Vivasure Medical Announces Andrew Glass as Chief Executive Officer

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

6 April 2021 – GALWAY, Ireland – Vivasure Medical® today announced Andrew Glass has assumed the role of Chief Executive Officer. Founder and former CEO Ger Brett will transition to serving as Chief Operating Officer.

“The company possesses a revolutionary technology to ensure success for the ever-increasing volume of percutaneous cardiovascular procedures performed every year around the world. I look forward to continuing to build on the tremendous progress Vivasure has made with its clinical and commercial programs under Ger’s exceptional leadership.”

Glass has extensive leadership, commercial operations and product development experience in the medical technology and cardiovascular fields. He held senior leadership roles at Abbott Laboratories for the past fifteen years, most recently as regional director at Abbott Vascular where he was responsible for the commercial operations for 13 European countries. Previously, he served in senior leadership positions in general management, business development, and marketing in Europe, Asia-Pacific, and the United States.

“I’m excited to be joining Vivasure during this momentous time of growth and development,” said Glass. “The company possesses a revolutionary technology to ensure success for the ever-increasing volume of percutaneous cardiovascular procedures performed every year around the world. I look forward to continuing to build on the tremendous progress Vivasure has made with its clinical and commercial programs under Ger’s exceptional leadership.”

Glass has a proven track record of aligning research and development efforts with commercial goals to drive the profitable and predictable growth of innovative technologies in the cardiovascular space.

“We’re thrilled to welcome an executive of Andrew’s caliber to the Vivasure team,” said Brett. “He’s an experienced and forward-thinking leader with a drive for growth. I look forward to working closely with him to continue making strides towards our mission to pioneer a new class of technology for percutaneous vessel closure.”

More To Explore